Why the study?
Uptake of direct factor Xa inhibitors varies, and guidance regarding their use in specific cancer sub-populations and clinical situations is lacking.
What is the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism?
What is the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism?
This consensus statement supports the use of direct factor Xa inhibitors as the treatment of choice for most patients with cancer-associated VTE, replacing LMWH.
No takes yet. Share an insight, caveat, or question.
Shifts standard of care from LMWH to direct factor Xa inhibitors for most cancer-associated VTE; reinforces Level 1 guideline consensus.
Cohen et al. (2023) conducted a review in Cancer-associated venous thromboembolism. Direct factor Xa inhibitors vs. Low molecular weight heparins (LMWH) was evaluated. Direct factor Xa inhibitors should be considered the treatment of choice for preventing VTE recurrence in most situations for patients with cancer-associated venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: